Business Context and Reporting Period
This Form 6-K filing is dated December 29, 2015, submitted by Prima BioMed Ltd (a foreign private issuer headquartered in Sydney, Australia). The filing serves to announce a new issue of securities and the application for quotation of additional securities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural announcement regarding a capital raise rather than a financial results report.
Material Changes
The material change disclosed is the execution of an agreement for a new issue of securities and the subsequent application for their quotation. No comparative financial data or operational changes are detailed in this specific text.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors. The primary focus is the regulatory notification of the new security issuance. The document is signed by Marc Voigt, Chief Executive Officer.
Investor Verification Checklist
- Verify the terms of the new security issue referenced in Exhibit 99.1.
- Confirm the total number of securities issued and the price per share.
- Check the status of the application for quotation of these additional securities.
- Review the full text of the agreement attached as Exhibit 99.1 for dilution impacts.